Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massiv

ABT fell 27% year to date, but FreeStyle Libre's 14% CGM growth and a forward P/E of 16 make it a buy.

Despite intensifying competition from Dexcom and Medtronic, FreeDM2 clinical data unlocks Abbott's expansion into the far larger Type 2 basal-insulin market.

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Abbott Laboratories didn't make the cut. Grab the names FREE today.

Abbott Laboratories (NYSE:ABT) at $90.53 is a Buy. The healthcare giant has been swept up in a sector-wide rotation out of defensive names, even as its diabetes franchise compounds and its medical devices unit posts double-digit growth.

Abbott spans medical devices, diagnostics, established pharmaceuticals, and nutrition, with Robert B. Ford as CEO. FreeStyle Libre, the continuous glucose monitor, is its fastest-growing engine. Shares have compressed from $127.12 at the Q3 2025 filing to today's level, dragged lower by sector multiple compression and concerns over the $21 billion Exact Sciences acquisition that closed March 23, 2026.

CGM sales hit $2.08 billion in Q1 2026, up 13.8% year over year. The FreeDM2 trial showed Type 2 patients on basal insulin using FreeStyle

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/buy-hold-sell-tech-compression-182027583.html)